Aptevo Therapeutics Inc. (APVO) Form 424B5 — Oct 30, 2026
Aptevo Therapeutics filed a 424B5 prospectus supplement on October 30, 2026 amending its at-the-market offering program with Roth Capital Partners, restoring capacity to sell up to $2,309,834 of additional common stock.
Key figures
- Cash Position
- 0
- Gross Proceeds
- 2309834
- Shares Offered
- Up to $2,309,834 aggregate offering price (number of shares not fixed)
- Public Float
- 6929502
- Shares Sold Under ATM
- 303157
- Gross Proceeds To Date
- 11799276
- Remaining ATMCapacity
- 2309834
- Last Reported Sale Price
- 1.34
- Non Affiliate Shares Outstanding
- 2665193
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.